Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
A Phase I study of an 'in-house' developed, novel, Class I, prototype medical device to facilitate vocalisation in participants with cuff-inflated tracheostomy tubes. Primary objective: To design and develop a device to deliver Above Cuff Vocalisation (ACV) that is safe, well tolerated and effective at producing a voice in tracheostomised patients in the Intensive Care Unit (ICU). Secondary objective: To evaluate whether more effective delivery of ACV has a significant impact on laryngeal function and recovery following new tracheostomy in ICU patients.
Description: To assess the effectiveness of the SEA CtV prototype device in producing a voice for cuff-inflated tracheostomy patients.
Measure: Effectiveness of vocalisation (Patient-reported voice VAS) Time: Daily for up to 7 daysDescription: (Objective scales FCS, NoWS, TOMS, GRBAS, recordings for volume and intelligibility); Cough count; Swallow count; e-Stim (threshold/max sensetivities); FEES (Laryngeal function scales Pen-Asp, SSRS, APS)
Measure: Voice rating Time: Daily for up to 7 daysDescription: Adverse events record (tracheosotmy tube displacement, surgical emphysema), adverse events log, setup safety tests (does the device stop appropriately)
Measure: Adverse events record Time: Daily for up to 7 daysDescription: Patient-reported subjective tolerability VAS; Staff-reported objective tolerability VAS; Patient-reported problems; ACV device use
Measure: Patient reported subjective tolerability Time: Daily for up to 7 daysDescription: Time to oral intake; Functional Swallowing Outcome; vocalisation; cuff deflation for >2 hours; ETT days; Trachy days; ICU days; hospital days; CCMDS organ supoort data
Measure: Time to first oral intake Time: Daily for up to 7 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports